Table 1.
Comparison of the clinical features between patients infected with the two types of genotype C, rt269L, and rt269I.
| Clinical factor | rt269L (n = 138) | rt269I (n = 82) | p-value |
|---|---|---|---|
| CH:HCC | 92:46 | 46:36 | ns |
| Sex, men | 63.04% | 64.63% | ns |
| HBeAg negative | 28.99% | 52.44% | ** |
| AST/ALT | 1.16 ± 0.78 | 1.42 ± 1.43 | ns |
| HBV-DNA (log10 copies/ml) | 6.47 ± 1.71 | 5.75 ± 1.62 | ** |
| HBsAg (log10 IU/ml) | 3.74 ± 0.61 | 3.41 ± 0.71 | *** |
| Age (years) | 42.04 ± 12.45 | 45.89 ± 12.61 | * |
| Bilirubin (mg/dL) | 0.99 ± 0.91 | 1.37 ± 1.71 | ** |
| Albumin (g/dL) | 4.01 ± 0.58 | 3.95 ± 0.63 | ns |
| Prothrombin time (INR) | 1.11 ± 0.18 | 1.14 ± 0.18 | ns |
| Platelet (109/L) | 169.93 ± 63.74 | 168.43 ± 81.93 | ns |
| Fibrosis-4 score | 4.05 ± 7.96 | 4.45 ± 5.42 | ns |
| Disease phase† | *** | ||
| 1 | 18.12% | 6.10% | |
| 2 | 52.90% | 41.46% | |
| 3 | 24.64% | 43.90% | |
| 4 | 4.35% | 8.54% |
CH, chronic hepatitis; HCC, hepatocellular carcinoma; AST, aspartate aminotransferase; ALT, alanine transaminase.
†
1. Immune-tolerant. 2. Immune-clearance. 3. HBeAg negative CHB. 4. Inactive carrier. Multi variate test were used.
Continuous variables were tested using the independent t-test and categorical variables were analyzed using MANOVA. ns, non-significant;
*
p < 0.05;
**
p < 0.01;
***
p < 0.001.